Skip to main content

Table 1 Baseline disease characteristic for bDMARD- naïve and TNFi-experienced patients in COAST-V and COAST-W

From: Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results

  COAST-V: bDMARD-naïve
(N = 329)
COAST-W: TNFi-experienced (N = 281)
Mean (range) SD Mean (range) SD
Age, years 41.6 (19–78) 11.7 46.3 (18–76) 12.3
Duration of disease since diagnosis, years 7.7 (0–43.9) 8.4 11.4 (0.3–43.8) 9.2
ASAS treatment response domains
 PtGA 7.1 (1–10) 1.6 7.9 (0–10) 1.6
 Spinal pain (BASDAI Q2) 7.3 (3–10) 1.5 8.2 (4–10) 1.3
 Function (BASFI) 6.2 (0.8–10) 1.9 7.2 (0.7–10) 1.7
 Stiffness (BASDAI Q5/Q6) 6.7 (1–10) 1.7 7.2 (2–10) 1.7
Other outcomes
 Fatigue (NRS) 6.8 (0–10) 1.7 7.3 (0–10) 1.7
 Fatigue (BASDAI Q1) 7.1 (2–10) 1.6 7.6 (3–10) 1.4
 Spinal pain at night 7.1 (2–10) 1.6 7.7 (0–10) 1.7
 Sleep (JSEQ) 8.2 (0–20) 5.2 10.2 (0–20) 5.6
 BASDAI 6.7 (2.8–10) 1.4 7.4 (3.4–10) 1.3
  1. ASAS Assessment of Spondyloarthritis International Society, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, bDMARD biologic disease-modifying antirheumatic drugs, JSEQ Jenkins Sleep Evaluation Questionnaire, N number of patients in analysis population, NRS numeric rating scale, PtGA patient global disease activity, Q question, SD standard deviation, TNFi tumor necrosis factor inhibitor.
  2. Ns and values are from the extended treatment period patient population. Data shown as mean (range) and SD